Product Description
Carisoprodol is used with rest, physical therapy, and other measures to relax muscles and relieve pain and discomfort caused by strains, sprains, and other muscle injuries. Carisoprodol is in a class of medications called skeletal muscle relaxants. It works by acting in the brain and nervous system to allow the muscles to relax. (Sourced from: https://medlineplus.gov/druginfo/meds/a682578.html)
Mechanisms of Action: GABA Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Bangladesh | Brazil | Canada | Chile | Colombia | Dominican Republic | Egypt | Hong Kong | India | Ireland | Italy | Mexico | Pakistan | Peru | Philippines | Portugal | Spain | Sweden | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Acute Pain | Pain Unspecified | Musculoskeletal Pain
Known Adverse Events: Dizziness | Headache
Company: Meda
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Burns Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| StrataSOMA | P2 |
Completed |
Burns Unspecified |
2024-03-13 |